Safety and efficacy of thymoglobulin (ATG) for cord blood transplantation for hematologic malignancies.

Next Previous
Trial Profile

Safety and efficacy of thymoglobulin (ATG) for cord blood transplantation for hematologic malignancies.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Fludarabine; Melphalan; Mycophenolate mofetil; Tacrolimus
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top